Assura (LON:AGR)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group in a research note issued on Thursday. They presently have a GBX 70 ($0.95) price target on the real estate investment trust’s stock. Jefferies Group’s price objective would indicate a potential upside of 14.75% from the stock’s previous close.
Several other equities analysts have also weighed in on the stock. Peel Hunt raised their price objective on shares of Assura from GBX 55 ($0.75) to GBX 57 ($0.77) and gave the company a “hold” rating in a research report on Thursday, November 16th. Liberum Capital restated a “buy” rating and set a GBX 68 ($0.92) price objective on shares of Assura in a research report on Thursday, November 16th.
Assura (LON AGR) traded down GBX 0.10 ($0.00) during trading hours on Thursday, hitting GBX 61 ($0.83). 2,440,000 shares of the stock traded hands, compared to its average volume of 2,910,000. Assura has a one year low of GBX 51.35 ($0.70) and a one year high of GBX 67.30 ($0.91). The company has a market cap of $1,450.00 and a price-to-earnings ratio of 871.43.
Assura plc is a United Kingdom-based healthcare real estate investment trust (REIT). The Company is a primary care property investor and developer. The Company develops, invests and manages a portfolio of primary care medical centers across the United Kingdom. The Company’s property portfolio includes Alwoodley Medical Centre, Leeds; Fleetwood Health and Wellbeing Centre, Fleetwood; Frome Medical Practice, Frome; Claremont Medical Centre, Surbiton; Elbury Moor Medical Centre; Grey Gable Surgery; Trellech Surgery; Bewdley Medical Centre; Malmesbury Primary Care Centre, Malmesbury, and Urmston Group Practice, Urmston.
Receive News & Ratings for Assura Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assura and related companies with MarketBeat.com's FREE daily email newsletter.